Back to Journals » Drug Design, Development and Therapy » Volume 2

A safety-modified SV40 Tag developed for human cancer immunotherapy

Authors Stephanie S Tseng-Rogenski, Mohamed S Arredouani, June F Escara-Wilke, Yilin C Neeley, Michael J Imperiale et al

Published 8 January 2008 Volume 2008:2 Pages 17—24

Stephanie S Tseng-Rogenski1, Mohamed S Arredouani2, June F Escara-Wilke1, Yilin C Neeley1, Michael J Imperiale3, Martin G Sanda1,2

1Department of Urology, School of Medicine, University of Michigan, Ann Arbor, MI, USA; 2Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 3Department of Microbiology and Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, USA

Abstract: Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenecity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy.
Keywords: modified SV-40 T antigen, recombinant vaccinia, cancer immunotherapy

Download Article [PDF] 

Readers of this article also read:

Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION–EGF) for targeting brain tumors

Shevtsov MA, Nikolaev BP, Yakovleva LY, Marchenko YY, Dobrodumov AV, Mikhrina AL, Martynova MG, Bystrova OA, Yakovenko IV, Ischenko AM

International Journal of Nanomedicine 2014, 9:273-287

Published Date: 3 January 2014

Selective laser sintering fabrication of nano-hydroxyapatite/poly-ε-caprolactone scaffolds for bone tissue engineering applications

Xia Y, Zhou PY, Cheng XS, Xie Y, Liang C, Li C, Xu SG

International Journal of Nanomedicine 2013, 8:4197-4213

Published Date: 1 November 2013

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, et al

Drug Design, Development and Therapy 2010, 4:117-126

Published Date: 18 June 2010

Antidiabetic Bis-Maltolato-OxoVanadium(IV): Conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B

Thomas Scior, Hans-Georg Mack, José Antonio Guevara García, Wolfhard Koch

Drug Design, Development and Therapy 2008, 2:221-231

Published Date: 18 November 2008

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

Michiko Yamamoto, Akira Takakura, Noriyuki Masuda

Drug Design, Development and Therapy 2008, 2:189-192

Published Date: 28 September 2008

Maraviroc in the treatment of HIV infection

Neelanjana Ray

Drug Design, Development and Therapy 2008, 2:151-161

Published Date: 20 August 2008

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

Glen C MacDonald, Michèle Rasamoelisolo, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, et al

Drug Design, Development and Therapy 2008, 2:105-114

Published Date: 25 June 2008

Modafinil in the treatment of excessive sleepiness

Jonathan RL Schwartz

Drug Design, Development and Therapy 2008, 2:71-85

Published Date: 20 May 2008